GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Surgery Partners Inc (NAS:SGRY) » Definitions » ROE %

Surgery Partners (Surgery Partners) ROE % : -0.20% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Surgery Partners ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Surgery Partners's annualized net income for the quarter that ended in Dec. 2023 was $-4 Mil. Surgery Partners's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1,996 Mil. Therefore, Surgery Partners's annualized ROE % for the quarter that ended in Dec. 2023 was -0.20%.

The historical rank and industry rank for Surgery Partners's ROE % or its related term are showing as below:

SGRY' s ROE % Range Over the Past 10 Years
Min: -23.52   Med: -6.1   Max: Negative Equity
Current: -0.6

During the past 12 years, Surgery Partners's highest ROE % was Negative Equity%. The lowest was -23.52%. And the median was -6.10%.

SGRY's ROE % is ranked worse than
61.6% of 612 companies
in the Healthcare Providers & Services industry
Industry Median: 4.035 vs SGRY: -0.60

Surgery Partners ROE % Historical Data

The historical data trend for Surgery Partners's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surgery Partners ROE % Chart

Surgery Partners Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.28 -18.70 -8.65 -3.54 -0.60

Surgery Partners Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.90 -5.03 3.80 -0.97 -0.20

Competitive Comparison of Surgery Partners's ROE %

For the Medical Care Facilities subindustry, Surgery Partners's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surgery Partners's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Surgery Partners's ROE % distribution charts can be found below:

* The bar in red indicates where Surgery Partners's ROE % falls into.



Surgery Partners ROE % Calculation

Surgery Partners's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-11.9/( (1998.2+1987.2)/ 2 )
=-11.9/1992.7
=-0.60 %

Surgery Partners's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-4/( (2004.6+1987.2)/ 2 )
=-4/1995.9
=-0.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Surgery Partners  (NAS:SGRY) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-4/1995.9
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4 / 2941.6)*(2941.6 / 6828.4)*(6828.4 / 1995.9)
=Net Margin %*Asset Turnover*Equity Multiplier
=-0.14 %*0.4308*3.4212
=ROA %*Equity Multiplier
=-0.06 %*3.4212
=-0.20 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-4/1995.9
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-4 / 210.8) * (210.8 / 558) * (558 / 2941.6) * (2941.6 / 6828.4) * (6828.4 / 1995.9)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -0.019 * 0.3778 * 18.97 % * 0.4308 * 3.4212
=-0.20 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Surgery Partners ROE % Related Terms

Thank you for viewing the detailed overview of Surgery Partners's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Surgery Partners (Surgery Partners) Business Description

Traded in Other Exchanges
N/A
Address
340 Seven Springs Way, Suite 600, Brentwood, TN, USA, 37027
Surgery Partners Inc is one of the few remaining independent ambulatory surgery center operators in the U.S. with national scale. The firm operates surgical facilities in approximately 30 states in partnership with physician groups and larger local healthcare systems. While surgical procedures drive a majority of the firm's revenue, the company also operates a clinical lab, urgent care facilities, and a handful of physician practices to provide additional healthcare services within the communities it serves. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.
Executives
Bain Capital Investors Llc director, 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Wayne S Deveydt director, officer: Chief Executive Officer 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
T. Devin O'reilly director, 10 percent owner C/O BAIN CAPITAL PRIVATE EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02149
Blair E Hendrix director, 10 percent owner
Andrew T. Kaplan director C/O BAIN CAPITAL PRIVATE EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116
Jason Eric Evans officer: EVP & Chief Operating Officer 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Harrison R. Bane officer: American Group President 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
David T Doherty officer: Chief Financial Officer 310 SEVEN SPRINGS WAY, BRENTWOOD TN 37027
Bradley R. Owens officer: National Group President 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Danielle Burkhalter officer: Chief Human Resources Officer 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Anthony Taparo officer: President, Atlantic Group 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Jennifer Baldock officer: Sr. VP, Gen Couns. & Sec. 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Marissa Brittenham officer: Chief Strategy Officer 310 SEVEN SPRINGS WAY, BRENTWOOD TN 37027
Bain Capital Fund Xi, L.p. director, 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Partners Xi, L.p. director, 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116